Primary (PDX) Glioblastoma Models
TD2 has established and validated the most comprehensive panel of first presentation and recurrent primary glioblastoma (GBM) models in the industry with over 40 models available for in vivo and in vitro analysis. These models provide a unique look into the various types of GBM disease types. Selection of the appropriate models for analysis is driven by a review of your drug’s specific mechanism of action (MOA) and subsequent interrogation of models that have the appropriate characterization. Fixed tissue can also be made available for analysis of novel markers.
All primary tumor models are validated as orthotopic models and are available to assess drug effects on tumor progression as single agents and in combination with standard therapies, including chemotherapies and radiation. These models are also available for in vitro analysis to assist in identifying mechanistic targets for your drug.
Most models are highly characterized, have standard of care (SOC) data, as well as some patient information on a subset of lines. Well-established protocols for efficient surgical implantation have been implemented to ensure an extremely high post surgery survival rate.
Standard GBM cell lines are also available for in vitro and in vivo studies. These models are well established and validated as both subcutaneous and orthotopic models.
Multiple Myeloma Mouse Model
TD2 is proud to offer drug efficacy studies in the Vk*Myc genetically engineered mouse model. This model is touted as a clinically predictive mouse model. Efficacy is assessed by monitoring treatment effects on the clinically-relevant M-protein levels.